<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hepatitis B virus immunization in infants, children, and adolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hepatitis B virus immunization in infants, children, and adolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hepatitis B virus immunization in infants, children, and adolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jan E Drutz, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Teresa K Duryea, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H548176596">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatitis B virus (HBV) immunization before HBV exposure is the most effective means to prevent HBV transmission. Hepatitis B immunization in infants, children, and adolescents will be discussed here, focusing on immunization of infants, children, and adolescents (&lt;18 years) in the United States. Our recommendations are generally consistent with those of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians and the American Association for the Study of Liver Diseases.
        </p>
        <p>
         HBV infection in children and adolescents and Hepatitis B immunization in adults (≥18 years) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5943.html" rel="external">
          "Clinical manifestations and diagnosis of hepatitis B virus infection in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116139.html" rel="external">
          "Management of hepatitis B virus infection in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">
          "Hepatitis B virus immunization in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H548176803">
         <span class="h1">
          HEPATITIS B INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         HBV is a deoxyribonucleic acid (DNA) hepadnavirus. The viral particle is composed of an outer lipoprotein envelope, which contains hepatitis B surface antigen (HBsAg), and an inner nucleocapsid, which consists of hepatitis B core antigen (HBcAg) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         HBV can be transmitted vertically from mother to infant during labor or delivery, through sexual intercourse, or by exposure to contaminated blood or body fluids. In utero transmission is uncommon. Infants born to HBsAg-positive women are at increased risk of HBV infection. Adolescents also are at increased risk as a result of sexual behavior or injection drug use. (See
         <a class="medical medical_review" href="/z/d/html/3630.html" rel="external">
          "Epidemiology, transmission, and prevention of hepatitis B virus infection", section on 'Transmission of HBV'
         </a>
         .)
        </p>
        <p>
         Each year in the United States an estimated 25,000 infants are born to women who are HBV carriers [
         <a href="#rid2">
          2
         </a>
         ]. As many as 90 percent of these infants will acquire acute HBV infection if no preventive measures are taken [
         <a href="#rid3">
          3,4
         </a>
         ]. Acquisition of HBV during infancy or early childhood is associated with an increased risk of developing chronic HBV infection compared with infection later in life  (
         <a class="graphic graphic_figure graphicRef101872" href="/z/d/graphic/101872.html" rel="external">
          figure 1
         </a>
         ). Approximately 25 percent of people infected with chronic HBV infection during infancy die prematurely from cirrhosis or liver cancer [
         <a href="#rid5">
          5-7
         </a>
         ]. Most people with chronic HBV infection remain asymptomatic until the onset of cirrhosis or end-stage liver disease and may be unaware of their infection, increasing the risk of transmission to household, sexual, or needle-sharing contacts. (See
         <a class="medical medical_review" href="/z/d/html/83476.html" rel="external">
          "Hepatitis B and pregnancy", section on 'Mother-to-child transmission'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3627.html" rel="external">
          "Hepatitis B virus: Clinical manifestations and natural history", section on 'Sequelae and prognosis of chronic HBV infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H548176105">
         <span class="h1">
          VACCINE FORMULATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vaccines available in the United States use recombinant DNA technology to express hepatitis B surface antigen in yeast cells. They do not contain thimerosal [
         <a href="#rid8">
          8-11
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Single antigen vaccines
         </strong>
         – Two single antigen (ie, monovalent)
         <a class="drug drug_pediatric" data-topicid="12938" href="/z/d/drug information/12938.html" rel="external">
          recombinant hepatitis B vaccines (conventional)
         </a>
         are available for use in children (&lt;18 years) in the United States [
         <a href="#rid1">
          1,12
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Engerix-B and
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recombivax HB
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These hepatitis B (HepB) vaccines are supplied in different concentrations and have different doses  (
         <a class="graphic graphic_table graphicRef60075" href="/z/d/graphic/60075.html" rel="external">
          table 1
         </a>
         ). They can be used interchangeably [
         <a href="#rid13">
          13
         </a>
         ], except that only the adult formulation of Recombivax HB can be used for the two-dose series in adolescents age 11 through 15 years [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Vaccinations available only for adults ≥age 18 years (ie, recombinant hepatitis B vaccine [CpG-adjuvanted], Heplisav-B; recombinant hepatitis B vaccine [trivalent], Prehevbrio) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">
          "Hepatitis B virus immunization in adults", section on 'Single-antigen vaccines'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combination vaccines
         </strong>
         – Recombinant HepB vaccine is a component in three combination vaccines, which can be used if the patient is due for the other vaccine components:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pediarix – Diphtheria and tetanus toxoids and acellular pertussis (DTaP), HepB (Engerix-B 10 mcg/mL), and inactivated
         <a class="drug drug_pediatric" data-topicid="12967" href="/z/d/drug information/12967.html" rel="external">
          poliovirus vaccine
         </a>
         (IPV) are typically administered at two, four, and six months of age; the DTaP-HepB-IPV combination vaccine should
         <strong>
          not
         </strong>
         be administered before six weeks or after seven years of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vaxelis – The combination DTaP, IPV,
         <em>
          Haemophilus influenzae
         </em>
         type b, and HepB recombinant vaccine is recommended for use at two, four, and six months of age and approved for use as a three-dose series in children six weeks through four years of age [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Twinrix – Hepatitis A and hepatitis B (Engerix-B 20 mcg); this vaccine is approved for individuals ≥18 years of age. (See
         <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">
          "Hepatitis B virus immunization in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Another combination vaccine (Comvax), which contained HepB vaccine and
         <em>
          Haemophilus influenzae
         </em>
         type b conjugate vaccine, was discontinued in 2014 [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interchangeability
         </strong>
         – The same brand of vaccine should be used whenever it is feasible, particularly for the first three doses in the series [
         <a href="#rid1">
          1,12,17
         </a>
         ]. If this is not feasible (eg, due to vaccine availability), an opportunity to administer vaccines to an eligible child should not be missed because the brand used for earlier doses is not available (or not known). Limited data suggest that using different brands to complete the primary series does not adversely affect vaccine safety or immunogenicity, but additional data supporting the interchangeability of acellular pertussis-containing HepB combination vaccines are necessary [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Storage
         </strong>
         – HepB vaccine should be refrigerated at a temperature between 36 and 46°F (2 and 8°C) [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H548176156">
         <span class="h1">
          ROUTINE INFANT IMMUNIZATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend immunization against HBV for all infants, as recommended by the Advisory Committee on Immunization Practices, American Academy of Pediatrics, American Academy of Family Physicians, and the World Health Organization (WHO) [
         <a href="#rid1">
          1,12,20-22
         </a>
         ]. Hepatitis B (HepB) vaccine is &gt;90 percent efficacious in preventing HBV infection and has few adverse effects. (See
         <a class="local">
          'Efficacy and effectiveness'
         </a>
         below and
         <a class="local">
          'Adverse reactions'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H167066815">
         <span class="h2">
          In the United States
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, the timing of the first dose of HepB vaccine and the need for
         <a class="drug drug_pediatric" data-topicid="13229" href="/z/d/drug information/13229.html" rel="external">
          hepatitis B immune globulin
         </a>
         (HBIG) are determined by the mother's hepatitis B surface antigen (HBsAg) status, the infant's gestational age, and the infant's birth weight  (
         <a class="graphic graphic_table graphicRef76345 graphicRef55139" href="/z/d/graphic/76345.html" rel="external">
          table 2A-B
         </a>
         ) [
         <a href="#rid1">
          1,23
         </a>
         ].
        </p>
        <p>
         Testing for HBsAg should be performed on all women at the first prenatal visit. (See
         <a class="medical medical_review" href="/z/d/html/83476.html" rel="external">
          "Hepatitis B and pregnancy", section on 'Maternal screening'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2018970930">
         <span class="h3">
          HBsAg-positive mother or mother with other evidence of HBV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         As soon as possible and within 12 hours after birth, infants born to women who are HBsAg-positive or women whose prenatal HBsAg results are not available at the time of delivery but who have other evidence of maternal HBV infection (eg, presence of hepatitis B deoxyribonucleic acid, positive hepatitis e antigen, known chronic hepatitis B infection) should receive  (
         <a class="graphic graphic_algorithm graphicRef116953" href="/z/d/graphic/116953.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1,23
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The first dose of single-antigen HepB vaccine intramuscularly (IM)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HBIG 0.5 mL IM
        </p>
        <p>
        </p>
        <p>
         HepB vaccine and HBIG should be administered at different anatomic sites and regardless of birth weight or maternal antiviral therapy for high hepatitis B viral loads during pregnancy. Infants who receive appropriate immunoprophylaxis may breastfeed immediately after birth.
        </p>
        <p>
         The risk of perinatal transmission among infants born to HBsAg-positive mothers is as high as 90 percent without immunoprophylaxis [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p>
         The schedule for subsequent doses depends upon the infant's birth weight  (
         <a class="graphic graphic_table graphicRef76345 graphicRef55139" href="/z/d/graphic/76345.html" rel="external">
          table 2A-B
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Birth weight ≥2 kg (4.4 pounds) – The second and third doses should be given at one and six months of age, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Birth weight &lt;2 kg (4.4 pounds) – Three additional doses should be given (at one, two to three, and six months of age
         <strong>
          or
         </strong>
         at two, four, and six months of age).
        </p>
        <p>
        </p>
        <p>
         Testing for HBsAg and antibody to HBsAg should be performed at 9 to 12 months of age. (See
         <a class="local">
          'Postvaccination serology'
         </a>
         below.)
        </p>
        <p>
         The benefits of prompt administration of HepB vaccine and HBIG and appropriate completion of the HepB vaccine series in preventing perinatal HBV infection in infants born to HBsAg-positive mothers have been demonstrated in randomized trials and in cohort studies [
         <a href="#rid26">
          26-29
         </a>
         ]. In a meta-analysis of three randomized trials, compared with placebo/no intervention, the combination of HepB vaccine and HBIG reduced HBV infection in infants born to HBsAg-positive women (4 versus 57 percent, relative risk [RR] 0.08, 95% CI 0.03-0.17) [
         <a href="#rid26">
          26
         </a>
         ]; in a meta-analysis of 10 randomized trials, the combination of HepB vaccine and HBIG was superior to HepB vaccine alone in reducing perinatal HBV infection (13 versus 24 percent, RR 0.54, 95% CI 0.41-0.73). In prospective surveillance studies of infants born to women with HBV infection who received HBIG and HepB vaccine and had postvaccination serologic testing, perinatal HBV infection occurred in &lt;2 percent [
         <a href="#rid27">
          27,28
         </a>
         ]. The risk of HBV was increased in infants who received &lt;3 doses of HepB vaccine compared with those who received ≥3 doses [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         The effectiveness of maternal antiviral therapy for high hepatitis B viral load during the third trimester of pregnancy combined with infant immunoprophylaxis on perinatal transmission are discussed separately. The effectiveness of maternal treatment without infant immunoprophylaxis is unknown [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/83476.html" rel="external">
          "Hepatitis B and pregnancy", section on 'Prevention of mother-to-child transmission'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H684037444">
         <span class="h3">
          HBsAg-negative mother, birth weight ≥2 kg
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the mother is HBsAg negative and the birth weight is ≥2 kg (4.4 pounds), the recommended schedule for HepB vaccine is as follows  (
         <a class="graphic graphic_table graphicRef76345" href="/z/d/graphic/76345.html" rel="external">
          table 2A
         </a>
         ) [
         <a href="#rid1">
          1,23
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First dose – During the birth hospitalization, within 24 hours of birth  (
         <a class="graphic graphic_algorithm graphicRef138545" href="/z/d/graphic/138545.html" rel="external">
          algorithm 2
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second dose – At 1 to 2 months of age
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Third dose – At 6 to 18 months of age (must be given at ≥24 weeks of age)
        </p>
        <p>
        </p>
        <p>
         Only single-antigen HepB vaccine can be used for the birth dose. Either single-antigen HepB vaccines or HepB-containing combination vaccines can be used for the second and third doses if the infant is ≥6 weeks old [
         <a href="#rid1">
          1,12
         </a>
         ]. Infants who receive the combination diphtheria and tetanus toxoids and acellular pertussis (DTaP)-HepB-inactivated
         <a class="drug drug_pediatric" data-topicid="12967" href="/z/d/drug information/12967.html" rel="external">
          poliovirus vaccine
         </a>
         (IPV) vaccine to complete the HepB series may receive a total of four doses (because DTaP and IPV are typically administered at two, four, and six months of age). In a randomized trial, receiving single-antigen HepB vaccine at birth in addition to HepB-containing combination vaccine at two, four, and six months of age did not increase the reactogenicity of a HepB-containing combination vaccine [
         <a href="#rid30">
          30
         </a>
         ]. Preterm infants with birth weight ≥2 kg (4.4 pounds) produce an immune response to the HepB vaccine comparable to that in term infants [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
         The minimum age for the final (third or fourth) dose of HepB vaccine is 24 weeks [
         <a href="#rid1">
          1
         </a>
         ]. The minimum interval between the second and third doses of a three-dose series or the third and fourth dose of a four-dose series is eight weeks. Longer intervals between the last two doses may result in higher antibody levels or longer duration of protective antibody [
         <a href="#rid33">
          33-36
         </a>
         ] but increase the risk for acquisition of HBV in persons who have a delayed response to vaccination. Preterm infants with birth weight ≥2 kg (4.4 pounds) produce an immune response to the HepB vaccine comparable to that in term infants [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
         Giving the first dose during the birth hospitalization is recommended because the birth dose serves as a "safety net" to prevent perinatal infection in infants born to HBsAg-positive mothers who are not identified (eg, because of errors in testing or failures in reporting of test results) and infants at risk for HBV infection after the perinatal period [
         <a href="#rid1">
          1
         </a>
         ]. In a cohort study of infants born to HBsAg-positive mothers, delay in administration of the first dose of HepB vaccine beyond one week of age was associated with increased risk of transmission (4.7 versus 22.2 to 33.3 percent) [
         <a href="#rid37">
          37
         </a>
         ]. In addition, in observational studies, receipt of the birth dose of HepB vaccine has been associated with higher rates of on-time completion of the HepB vaccine series and timely receipt of other infant immunizations [
         <a href="#rid38">
          38-40
         </a>
         ], without compromising immunogenicity [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H684037633">
         <span class="h3">
          HBsAg-negative mother, birth weight &lt;2 kg
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the mother is HBsAg-negative, the birth weight is &lt;2 kg (4.4 pounds), and the infant is medically stable, the infant is immunized at one month of age or at hospital discharge if discharge occurs before one month of age  (
         <a class="graphic graphic_table graphicRef55139" href="/z/d/graphic/55139.html" rel="external">
          table 2B
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef138545" href="/z/d/graphic/138545.html" rel="external">
          algorithm 2
         </a>
         ) [
         <a href="#rid1">
          1,12,23
         </a>
         ].
        </p>
        <p>
         HepB vaccine is less immunogenic in preterm infants with birth weights &lt;2 kg (4.4 pounds) than in term infants [
         <a href="#rid31">
          31,41-43
         </a>
         ]. However, preterm infants who are medically stable respond to HepB vaccine by one month of age regardless of birth weight or gestational age [
         <a href="#rid31">
          31,32,43-47
         </a>
         ].
        </p>
        <p>
         Immunization of low-risk preterm, low birth weight infants by one month of age permits greater flexibility for initiating the routine immunization schedule during hospitalization, may decrease the number of simultaneous immunizations at six to eight weeks of age, provides timely protection for infants who may require blood products or surgery, and increases the likelihood that HepB vaccine and other recommended childhood vaccines will be completed on time [
         <a href="#rid38">
          38-40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H684038557">
         <span class="h3">
          Mother's HBsAg status unknown, birth weight ≥2 kg
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the mother's HBsAg status is unknown and she has no evidence suggestive of hepatitis B infection, and the infant's birth weight is ≥2 kg (4.4 pounds), the first dose of single-antigen HepB vaccine should be administered within 12 hours of birth  (
         <a class="graphic graphic_table graphicRef76345" href="/z/d/graphic/76345.html" rel="external">
          table 2A
         </a>
         ) while testing the mother to determine her HBsAg status  (
         <a class="graphic graphic_algorithm graphicRef138545" href="/z/d/graphic/138545.html" rel="external">
          algorithm 2
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. The schedule for the remaining doses of HepB vaccine and the need for HBIG depends upon the mother's HBsAg status once it is determined. If she is found to be HBsAg-positive, HBIG 0.5 mL should be given by one week of age. If maternal status remains unknown, HBIG 0.5 mL should be administered at hospital discharge or within seven days (whichever is first) [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="local">
          'HBsAg-positive mother or mother with other evidence of HBV infection'
         </a>
         above and
         <a class="local">
          'HBsAg-negative mother, birth weight ≥2 kg'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H684038564">
         <span class="h3">
          Mother's HBsAg status unknown, birth weight &lt;2 kg
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the mother's HBsAg status is unknown and the infant's birth weight is &lt;2 kg (4.4 pounds), the infant should receive single-antigen-HepB vaccine within 12 hours of birth and HBIG 0.5 mL within 12 hours of birth if maternal status cannot be determined by that time or is positive  (
         <a class="graphic graphic_algorithm graphicRef138545" href="/z/d/graphic/138545.html" rel="external">
          algorithm 2
         </a>
         and
         <a class="graphic graphic_table graphicRef55139" href="/z/d/graphic/55139.html" rel="external">
          table 2B
         </a>
         ). The dose of HepB vaccine that is administered within 12 hours of birth is not counted; the infant will require three additional doses of HepB vaccine to complete the immunization series. The schedule for the three doses and subsequent management vary according to the mother's HBsAg status. Infants whose mother's HBsAg status will remain unknown indefinitely (eg, those who were abandoned or safely surrendered after home birth) should be managed as if the mother was HBsAg-positive. (See
         <a class="local">
          'HBsAg-positive mother or mother with other evidence of HBV infection'
         </a>
         above and
         <a class="local">
          'HBsAg-negative mother, birth weight &lt;2 kg'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H167067066">
         <span class="h2">
          In other countries
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine immunization schedules vary from country to country. Schedules for individual countries are available through the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fimmunizationdata.who.int%2Fpages%2Fschedule-by-disease%2Fhepatitisb.html%3FISO_3_CODE%3D%26TARGETPOP_GENERAL%3D&amp;token=7L%2FT4Errpc8fUp0gdI9jNKxnFqJ3bBNd%2Bp4jGsjgvadbbr%2BIMv6TX4mamxi346d4qFmNQRSPHB7jLjUtqOAIPvKkXyXaNdSeCrtwRZSoWSE%2BWkHkHjapjjFEUeryMDr2Od7SOqP%2BYCI1HB6b%2ByMsKw%3D%3D&amp;TOPIC_ID=101483" target="_blank">
          WHO
         </a>
         .
        </p>
        <p class="headingAnchor" id="H350537414">
         <span class="h2">
          Efficacy and effectiveness
         </span>
         <span class="headingEndMark">
          —
         </span>
         The efficacy and effectiveness of HepB immunization vary depending upon the outcome (eg, protection from disease or levels of antibody correlated with protection) and the number of doses received.
        </p>
        <p>
         Between the early 1990s, when HepB vaccine was added to the routine infant immunization schedule in the United States, and 2004, the rate of acute HBV in children and adolescents &lt;19 years in the United States decreased by 94 percent  (
         <a class="graphic graphic_figure graphicRef101870" href="/z/d/graphic/101870.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
         The long-term efficacy of infant HepB immunization programs was demonstrated in 30-year follow-up of a cluster randomized trial comparing universal neonatal HepB vaccine and no vaccine; none of the study participants received HBIG [
         <a href="#rid48">
          48
         </a>
         ]. Neonatal hepatitis B vaccine protected against developing primary liver cancer (efficacy 84 percent, 95% CI 23-97), mortality from infant fulminant hepatitis (efficacy 69 percent, 95% CI 34-85), and severe end-stage liver disease (efficacy 70 percent, 95% CI 15-89).
        </p>
        <p>
         The long-term effectiveness of infant HepB immunization programs was demonstrated in 30-year follow-up of the national program in Taiwan, which was introduced for high-risk infants in 1984 and expanded to include all newborns in 1986 and preschool-and school age children in 1988 [
         <a href="#rid49">
          49
         </a>
         ]. Coverage rates were &gt;88 percent [
         <a href="#rid49">
          49
         </a>
         ]. Between 1977 to 1980 and 2009 to 2011, the incidence of hepatocellular carcinoma among individuals 5 to 29 years of age declined by &gt;80 percent (from 1.1 to 0.09 per 100,000 person-years). Hepatitis B-related mortality declined by &gt;90 percent (from 5.8 to 0.2 per 100,000 person-years for infant fulminant hepatitis, from 0.65 to 0.02 per 100,000 person-years for chronic liver disease, and from 0.81 to 0.05 per 100,000 person-years for hepatocellular carcinoma).
        </p>
        <p class="headingAnchor" id="H684036953">
         <span class="h2">
          Duration of immunity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaccine-induced immunity to hepatitis B virus is long lasting [
         <a href="#rid50">
          50-52
         </a>
         ]. Routine booster doses of HepB vaccine are not necessary for children and adolescents with normal immune status [
         <a href="#rid1">
          1
         </a>
         ]. The need for additional doses of HepB vaccine in immune-compromised children and adolescents is discussed below. (See
         <a class="local">
          'Immune-compromised patients'
         </a>
         below.)
        </p>
        <p>
         In a cohort of 423 children from an area of low HBV endemicity who completed the HepB vaccination series by 12 months of age, &gt;90 percent demonstrated a protective response to a challenge dose of vaccine at age 16 through 19 years [
         <a href="#rid53">
          53
         </a>
         ]. A similar rate of response (88 percent) was noted 30 years after completion of the HepB vaccine series in 85 Alaska Native adults and children [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H684037343">
         <span class="h1">
          VACCINE ADMINISTRATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatitis B (HepB) vaccine dose (and corresponding volume) varies with the age of the recipient and whether they are receiving hemodialysis or are immune compromised  (
         <a class="graphic graphic_table graphicRef60075" href="/z/d/graphic/60075.html" rel="external">
          table 1
         </a>
         ). If an adult dose of the vaccine is administered to an infant, the dose can be counted as valid and does not need to be repeated; the next dose should be given according to the routine schedule [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         HepB vaccines are administered intramuscularly (IM)  (
         <a class="graphic graphic_table graphicRef60863" href="/z/d/graphic/60863.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid55">
          55
         </a>
         ]. HepB vaccine administered by any route other than IM should not be counted as valid and should be repeated. Administration of immunizations in children with bleeding disorders is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">
          "Standard immunizations for children and adolescents: Overview", section on 'Other special circumstances'
         </a>
         .)
        </p>
        <p>
         HepB vaccines typically are administered in the anterolateral thigh (for children &lt;3 years) or deltoid (for children ≥3 years)  (
         <a class="graphic graphic_table graphicRef60863" href="/z/d/graphic/60863.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid55">
          55
         </a>
         ]. HepB administered at any site other than the deltoid or anterolateral thigh should not be counted as valid and should be repeated [
         <a href="#rid56">
          56-59
         </a>
         ]. (See
         <a class="local">
          'Catch-up immunization'
         </a>
         below.)
        </p>
        <p>
         Different limbs should be used if HepB vaccine and
         <a class="drug drug_pediatric" data-topicid="13229" href="/z/d/drug information/13229.html" rel="external">
          hepatitis B immune globulin
         </a>
         (HBIG) are administered at the same time (ie, same day, same clinic visit) [
         <a href="#rid55">
          55
         </a>
         ]. The injections may be administered in any order. There is no minimum interval between administration of HepB vaccine and HBIG if they are not administered at the same time.
        </p>
        <p>
         HepB vaccine may be administered at the same clinic visit as other routine childhood immunizations  (
         <a class="graphic graphic_figure graphicRef82617 graphicRef58209" href="/z/d/graphic/82617.html" rel="external">
          figure 3A-B
         </a>
         ) [
         <a href="#rid55">
          55,60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H684034809">
         <span class="h1">
          CATCH-UP IMMUNIZATION
         </span>
        </p>
        <p class="headingAnchor" id="H684035234">
         <span class="h2">
          Target groups
         </span>
         <span class="headingEndMark">
          —
         </span>
         Catch-up hepatitis B (HepB) vaccine is indicated for [
         <a href="#rid1">
          1,12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All children and adolescents &lt;19 years who are unvaccinated or incompletely vaccinated against HBV  (
         <a class="graphic graphic_table graphicRef116656" href="/z/d/graphic/116656.html" rel="external">
          table 4
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/3630.html" rel="external">
          "Epidemiology, transmission, and prevention of hepatitis B virus infection", section on 'Transmission of HBV'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children and adolescents with unknown or uncertain vaccination status
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children and adolescents who received doses of HepB vaccine that were administered inappropriately, unless serologic testing (if performed) indicates that they responded adequately (see
         <a class="local">
          'Postvaccination serology'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Inappropriate administration includes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intervals that were too short (eg, &lt;4 weeks between the first and second dose; &lt;8 weeks between the second and third dose; or &lt;16 weeks between the first and third dose); doses administered four or fewer days less than these intervals are considered valid [
         <a href="#rid1">
          1
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Receipt of the final dose of the primary infant series at &lt;24 weeks of age; doses administered four or fewer days less than 24 weeks (ie, at ≥164 days) are considered valid [
         <a href="#rid1">
          1
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Administration by a route other than intramuscular
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Administration at a site other than the anterolateral thigh or deltoid
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H684036694">
         <span class="h2">
          Need for prevaccination screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prevaccination serologic testing is not routinely necessary before initiating or resuming HepB immunization in children or adolescents. The risk of adverse effects is not increased in persons who are immune to HBV because of past infection or immunization [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         However, in patients at high risk of HBV infection  (
         <a class="graphic graphic_table graphicRef116656" href="/z/d/graphic/116656.html" rel="external">
          table 4
         </a>
         ), prevaccination testing can identify acute or chronic HBV infection or immunity to HBV infection. Serologic testing should not be a barrier to immunization [
         <a href="#rid61">
          61
         </a>
         ]. In most cases the first dose of vaccine should be administered immediately after blood is obtained for serology (ie, without waiting for results). When serologic testing and HepB vaccination are to be performed on the same day, blood for serology should be obtained before immunization. Transient HBsAg positivity (&lt;21 days) has been reported following HepB vaccination [
         <a href="#rid62">
          62-64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5943.html" rel="external">
          "Clinical manifestations and diagnosis of hepatitis B virus infection in children and adolescents", section on 'Screening'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H684035240">
         <span class="h2">
          Schedule
         </span>
         <span class="headingEndMark">
          —
         </span>
         The HepB vaccine series does not need to be restarted if it was interrupted [
         <a href="#rid1">
          1
         </a>
         ]. The remaining doses should be administered as soon as possible, adhering to the minimum intervals: 4 weeks between the first and second dose; 8 weeks between the second and third dose; and 16 weeks between the first and third dose.
        </p>
        <p>
         Unvaccinated adolescents age 11 through 15 years have the option of a two-dose series using the adult formulation of the Recombivax HB vaccine (10 mcg/1 mL per dose)  (
         <a class="graphic graphic_table graphicRef60075" href="/z/d/graphic/60075.html" rel="external">
          table 1
         </a>
         ); the two doses are administered four to six months apart [
         <a href="#rid65">
          65
         </a>
         ]. Both doses must be administered before 16 years of age. If the second dose is not administered until after the 16
         <sup>
          th
         </sup>
         birthday, a pediatric formulation should be used for the second dose, and the adolescent should receive a third dose (pediatric formulation) at least 8 weeks after the second dose and 16 weeks after the first dose. The need to achieve completion of the vaccine series should be considered when choosing the two- or three-dose schedule for adolescents 11 through 15 years of age.
        </p>
        <p class="headingAnchor" id="H184444107">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H259022155">
         <span class="h2">
          Immune-compromised patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Issues related to hepatitis B immunization for immunocompromised patients, including those with human immunodeficiency virus (HIV) infection, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">
          "Immunizations in hematopoietic cell transplant candidates and recipients", section on 'Hepatitis B'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">
          "Immunizations in solid organ transplant candidates and recipients", section on 'Hepatitis B'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106521.html" rel="external">
          "Immunizations in patients with inborn errors of immunity", section on 'Killed, inactivated, mRNA, or subcomponent vaccines'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3706.html" rel="external">
          "Immunizations in persons with HIV", section on 'Hepatitis B vaccine'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H350537732">
         <span class="h2">
          Travelers to HBV-endemic areas
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatitis B vaccine for travelers to countries with intermediate or high
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fyellowbook%2F2018%2Finfectious-diseases-related-to-travel%2Fhepatitis-b&amp;token=ca0vk4z61eMR4W9wfxx5G3sqSUyy3caG6vnexa7UaCgGHu6EIepr0FGTytJbcLZYSP%2FRSKySACG5UcGefpfaseefS8eBakslP02czRDeld3vLygsz8rEyw22BFAIhHKL&amp;TOPIC_ID=101483" target="_blank">
          hepatitis B virus endemicity
         </a>
         (
         <a class="graphic graphic_table graphicRef51820" href="/z/d/graphic/51820.html" rel="external">
          table 5
         </a>
         ) is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3890.html" rel="external">
          "Immunizations for travel", section on 'Hepatitis B vaccine'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H548176551">
         <span class="h1">
          CONTRAINDICATIONS AND PRECAUTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         HBV vaccination is contraindicated in individuals with a history of hypersensitivity to yeast or to any vaccine component  (
         <a class="graphic graphic_table graphicRef101869" href="/z/d/graphic/101869.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid1">
          1,55
         </a>
         ].
        </p>
        <p>
         Acute moderate to severe illness is a precaution to HBV vaccination [
         <a href="#rid55">
          55
         </a>
         ]. Vaccination generally should be postponed until after recovery to avoid superimposing adverse effects of the vaccine on the underlying illness and diagnostic confusion between manifestations of the underlying illness and adverse effects. However, decisions should be individualized.
        </p>
        <p>
         Vaccination is
         <strong>
          not
         </strong>
         contraindicated in persons with a history of multiple sclerosis, Guillain-Barré syndrome, autoimmune disease, or other chronic disorders; nor is it contraindicated in pregnancy [
         <a href="#rid1">
          1,55,66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H614585335">
         <span class="h1">
          ADVERSE REACTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatitis B (HepB) vaccines are safe. The most frequently reported side effects are pain at the injection site in 3 to 29 percent, erythema in 3 percent, and fever &gt;37.7°C (99°F) in 1 to 6 percent [
         <a href="#rid1">
          1
         </a>
         ]. Administration of the first dose during the birth hospitalization has not been associated with increased rates of newborn sepsis evaluations [
         <a href="#rid67">
          67
         </a>
         ]. In a large cohort, the risk of anaphylaxis after a HepB-containing vaccine was 1 per 1.1 million doses (95% CI 0.1-3.9) [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         In the United States, any clinically significant or unexpected adverse events that occur after administration of HepB vaccine should be reported to the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2Findex.html&amp;token=8m3rK0tzv73hmwLVujPJP%2FVrZTr5LmKIlDf%2BMKp07YKCkZawMmw76Mlq0N%2Fh3R%2BM&amp;TOPIC_ID=101483" target="_blank">
          Vaccine Adverse Event Reporting System
         </a>
         (telephone number 1-800-822-7967). (See
         <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">
          "Standard immunizations for children and adolescents: Overview", section on 'Reporting adverse events'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H167067091">
         <span class="h1">
          POSTVACCINATION SEROLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serologic testing to assess antibody response to hepatitis B (HepB) vaccine usually is not necessary for immunocompetent children and adolescents. However, it should be performed in specific populations, including [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="headingAnchor" id="H773444165">
         <span class="h2">
          Infants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postvaccination serology should be obtained in infants born to [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Women who are HBsAg-positive
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Women whose prenatal HBsAg results were not available at the time of delivery but who have other evidence suggestive of hepatitis B infection (eg, presence of hepatitis B deoxyribonucleic acid, positive hepatitis B e antigen, known to have chronic hepatitis B)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Women whose HBsAg-status cannot be determined (eg, infants who were abandoned or safely surrendered shortly after birth)
        </p>
        <p>
        </p>
        <p>
         Postvaccination serology (
         <strong>
          both
         </strong>
         HBsAg and antibody to HBsAg [anti-HBs]  (
         <a class="graphic graphic_table graphicRef101871" href="/z/d/graphic/101871.html" rel="external">
          table 7
         </a>
         )) should be obtained after receiving ≥3 doses of HepB vaccine, usually at 9 to 12 months of age or one to two months after the last dose of HepB vaccine if immunization is delayed [
         <a href="#rid1">
          1
         </a>
         ]. Obtaining serology soon after the vaccine series is completed is supported by observational studies demonstrating that levels of anti-HBs decreased with increasing intervals from the last dose of HepB vaccine, resulting in unnecessary revaccination when serology was obtained later [
         <a href="#rid69">
          69,70
         </a>
         ].
        </p>
        <p>
         Serology should not be performed before nine months of age because
         <a class="drug drug_pediatric" data-topicid="13229" href="/z/d/drug information/13229.html" rel="external">
          hepatitis B immune globulin
         </a>
         (HBIG) may still be present; it should not be performed sooner than four weeks after the last dose of HepB vaccine because of the possibility of transient (&lt;21 days) HBsAg-positivity related to the vaccine [
         <a href="#rid62">
          62,63
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HBsAg-positive infants
         </strong>
         – Infants who are HBsAg-positive
         <strong>
          at any time during postvaccination testing
         </strong>
         should be referred for evaluation of chronic liver disease  (
         <a class="graphic graphic_algorithm graphicRef116953" href="/z/d/graphic/116953.html" rel="external">
          algorithm 1
         </a>
         ). Household contacts who have not been vaccinated against HBV should be vaccinated. (See
         <a class="medical medical_review" href="/z/d/html/5943.html" rel="external">
          "Clinical manifestations and diagnosis of hepatitis B virus infection in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116139.html" rel="external">
          "Management of hepatitis B virus infection in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HBsAg-negative infants
         </strong>
         – Management of infants who are HBsAg-negative depends upon the concentration of anti-HBs  (
         <a class="graphic graphic_algorithm graphicRef116953" href="/z/d/graphic/116953.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anti-HBs ≥10 milli-international units (mIU)/mL
         </strong>
         – Infants who are HBsAg-negative and have anti-HBs concentration ≥10 mIU/mL are immune to HBV. Additional doses of HepB vaccine and serologic testing are not necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anti-HBs &lt;10 mIU/mL
         </strong>
         – Infants whose anti-HBs is &lt;10 mIU/mL remain susceptible to HBV  (
         <a class="graphic graphic_table graphicRef101871" href="/z/d/graphic/101871.html" rel="external">
          table 7
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Preferred regimen
         </strong>
         – The preferred regimen for infants who remain susceptible after the primary infant series is one dose of HepB vaccine followed by measurement of anti-HBs and HBsAg one to two months later [
         <a href="#rid1">
          1
         </a>
         ]. This approach is supported by observational studies in which &gt;94 percent of infants born to HBsAg-positive women achieved anti-HBs ≥10 mIU/mL with one additional dose of HepB vaccine [
         <a href="#rid70">
          70-72
         </a>
         ]. Compared with the alternative regimen, it reduces the number of vaccine doses, the duration of case management, and cost for most infants.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         HBsAg-negative infants whose anti-HBs remains &lt;10 mIU/mL after the first additional dose of HepB vaccine should receive two more doses, separated by at least eight weeks, with measurement of anti-HBs and HBsAg one to two months later. In a cohort study, all 45 HBV-susceptible children who did not respond to perinatal HepB immunization responded to a second HepB vaccine series, and &gt;70 percent had protective titers four years later [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Alternative regimen
         </strong>
         – An alternative regimen for infants who remain susceptible after the primary infant series is three doses of HepB vaccine (at zero, one to two, and six months) followed by measurement of anti-HBs and HBsAg one to two months after the third dose. The alternative regimen may be warranted depending on clinical circumstances or caregiver preference.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HBsAg-negative children whose anti-HBs levels remain &lt;10 mIU/mL after two complete series of HepB vaccines are considered to be "nonresponders" and susceptible to HBV. Available data do not suggest a benefit from additional doses of HepB vaccine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Caregivers of nonresponders should receive information about precautions to prevent HBV infection, and the nonresponders should receive appropriate postexposure prophylaxis if they are exposed. (See
         <a class="medical medical_review" href="/z/d/html/3630.html" rel="external">
          "Epidemiology, transmission, and prevention of hepatitis B virus infection", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the United States, postvaccination serology results should be reported to
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fvpd%2Fhepb%2Fhcp%2Fperinatal-contacts.html&amp;token=0Pg%2FQQ83cn1K58%2FZm56Thig8pg%2FcBDyFs81OHU538tyR35Crrp0LpAWqGYFX2LcMcXqwrBDSJnK6xgFc9KTYKiwkJp4SQPX9IPx6FPRezX0%3D&amp;TOPIC_ID=101483" target="_blank">
          perinatal hepatitis B program coordinators
         </a>
         who can assist caregivers in assuring infant protection [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3667422183">
         <span class="h2">
          Older children and adolescents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodialysis patients
         </strong>
         – Hemodialysis patients may have a reduced response to HepB vaccine. Serologic testing (anti-HBs) one to two months after administration of the last dose of the primary HepB vaccine series is recommended to determine the need for revaccination [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, we obtain annual anti-HBs testing for hemodialysis patients and administer a booster dose of HepB vaccine when the anti-HBs concentration is &lt;10 mIU/mL, in agreement with the United States Advisory Committee on Immunization Practices (ACIP), American Academy of Pediatrics (AAP), and the American Association for the Study of Liver Diseases [
         <a href="#rid1">
          1,12,74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immune-compromised patients
         </strong>
         – The immune response to HepB vaccine is reduced in children who are immune compromised [
         <a href="#rid75">
          75-80
         </a>
         ]. However, there is no standard approach to postvaccination testing and provision of booster doses. Annual testing for anti-HBs and provision of a booster dose of HepB vaccine when anti-HBs concentration is &lt;10 mIU/mL is a reasonable strategy for prevention of HBV infection in immune-compromised children and adolescents with ongoing risk of HBV exposure and is suggested by the ACIP and AAP [
         <a href="#rid1">
          1,12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional considerations regarding HepB immunization for immune-compromised patients are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">
          "Immunizations in hematopoietic cell transplant candidates and recipients", section on 'Hepatitis B'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">
          "Immunizations in solid organ transplant candidates and recipients", section on 'Hepatitis B'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106521.html" rel="external">
          "Immunizations in patients with inborn errors of immunity", section on 'Killed, inactivated, mRNA, or subcomponent vaccines'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3706.html" rel="external">
          "Immunizations in persons with HIV", section on 'Hepatitis B vaccine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sexual partners of HBsAg-positive persons
         </strong>
         – Sexual partners of HBsAg-positive persons are at risk of recurrent exposure to HBV, and it is important to make sure that they have a protective response to the primary vaccine series.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Those who have anti-HBs concentrations ≥10 mIU/mL are considered immune to HBV and do not require additional testing (unless they are immune compromised).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Those who have anti-HBs concentrations &lt;10 mIU/mL should be revaccinated according to an age-appropriate schedule and have repeat measurement of anti-HBs one to two months after completion. Those who do not respond to a second series of vaccines should be tested for HBsAg.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Those who are HBsAg-positive should be referred for evaluation of chronic liver disease. Their household contacts who have not been vaccinated against HBV should be vaccinated. (See
         <a class="medical medical_review" href="/z/d/html/5943.html" rel="external">
          "Clinical manifestations and diagnosis of hepatitis B virus infection in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116139.html" rel="external">
          "Management of hepatitis B virus infection in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Those who are HBsAg-negative should be considered to be susceptible to HBV. They should receive information about precautions to prevent HBV infection and should receive appropriate postexposure prophylaxis if they are exposed. (See
         <a class="medical medical_review" href="/z/d/html/3630.html" rel="external">
          "Epidemiology, transmission, and prevention of hepatitis B virus infection", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H684036587">
         <span class="h1">
          POSTEXPOSURE IMMUNIZATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postexposure HepB immunization (with or without adjunctive
         <a class="drug drug_pediatric" data-topicid="13229" href="/z/d/drug information/13229.html" rel="external">
          hepatitis B immune globulin
         </a>
         ) is recommended for unvaccinated or incompletely vaccinated children and adolescents with exposure to blood or infectious secretions (eg, bite, needlestick, sexual assault). (See
         <a class="medical medical_review" href="/z/d/html/3630.html" rel="external">
          "Epidemiology, transmission, and prevention of hepatitis B virus infection", section on 'Prevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H548176815">
         <span class="h1">
          RESOURCES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Resources related to immunization in infants and children include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpatient-care%2Fimmunizations%2F&amp;token=IQxLzDq4doJGUgaZgeIY01qsm8D6OPt1e2CZs7qNDD9Vki1c5XPFvhIarxbXlaH%2FgCiVnpr391CqcLRvxCctPg%3D%3D&amp;TOPIC_ID=101483" target="_blank">
          American Academy of Pediatrics
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLMlA2kPbc%2FqiOcC%2F32sLF4g1y%2BAHPIpB3%2FyasJ9MUj3%2F&amp;TOPIC_ID=101483" target="_blank">
          Centers for Disease Control and Prevention
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.immunize.org%2F&amp;token=bJ98wEjwYbR6KcGnbD%2BLoejSdbdtDpI4EQKn%2BtqVzWf7RcpJipfWejk%2Bgy%2BCZPR%2F&amp;TOPIC_ID=101483" target="_blank">
          Immunization Action Coalition
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fcurrent-vis.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLAH%2FK5ePuSCWLS93Qnaa3r%2F5qdQw%2FNYQGK1y%2BHqFU7TkRZLnBxvqrSwSUrCQcXZVSA%3D%3D&amp;TOPIC_ID=101483" target="_blank">
          Vaccine information statement for hepatitis B vaccine
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fhealth-topics%2Fvaccines-and-immunization%23tab%3Dtab_1&amp;token=sSvPxFQw%2FW8petBuExUNJFksz1RKd2IO1NpP82VPqNHer3d29IxVo4ElKIp%2BqUTxxIPiAxTTFHWTfb6RjAm92zwRENv8KpcsZ4vh6IIWNdA%3D&amp;TOPIC_ID=101483" target="_blank">
          World Health Organization
         </a>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H229810095">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111308.html" rel="external">
          "Society guideline links: Hepatitis B vaccination"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/109228.html" rel="external">
          "Society guideline links: Immunizations in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H548176668">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15382.html" rel="external">
          "Patient education: Hepatitis B (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15741.html" rel="external">
          "Patient education: Vaccines for babies and children age 0 to 6 years (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15742.html" rel="external">
          "Patient education: Vaccines for children age 7 to 18 years (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4575.html" rel="external">
          "Patient education: Hepatitis B (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/1214.html" rel="external">
          "Patient education: Why does my child need vaccines? (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/1216.html" rel="external">
          "Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/1218.html" rel="external">
          "Patient education: Vaccines for children age 7 to 18 years (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H548176602">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Routine infant immunization
         </strong>
         – We recommend universal hepatitis B (HepB) immunization for infants (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). In the United States, HepB vaccine usually is administered at birth, 1 to 2 months, and 6 to 18 months of age  (
         <a class="graphic graphic_figure graphicRef82617" href="/z/d/graphic/82617.html" rel="external">
          figure 3A
         </a>
         ); the optimal intervals and need for
         <a class="drug drug_pediatric" data-topicid="13229" href="/z/d/drug information/13229.html" rel="external">
          hepatitis B immune globulin
         </a>
         (HBIG) are determined by the mother's hepatitis B surface antigen (HBsAg) status and the infant's gestational age and birth weight  (
         <a class="graphic graphic_algorithm graphicRef116953" href="/z/d/graphic/116953.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef138545" href="/z/d/graphic/138545.html" rel="external">
          algorithm 2
         </a>
         and
         <a class="graphic graphic_table graphicRef76345 graphicRef55139" href="/z/d/graphic/76345.html" rel="external">
          table 2A-B
         </a>
         ). HepB immunization schedules for other countries are available through the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fimmunizationdata.who.int%2Fpages%2Fschedule-by-disease%2Fhepatitisb.html%3FISO_3_CODE%3D%26TARGETPOP_GENERAL%3D&amp;token=7L%2FT4Errpc8fUp0gdI9jNKxnFqJ3bBNd%2Bp4jGsjgvadbbr%2BIMv6TX4mamxi346d4qFmNQRSPHB7jLjUtqOAIPvKkXyXaNdSeCrtwRZSoWSE%2BWkHkHjapjjFEUeryMDr2Od7SOqP%2BYCI1HB6b%2ByMsKw%3D%3D&amp;TOPIC_ID=101483" target="_blank">
          World Health Organization
         </a>
         . (See
         <a class="local">
          'Routine infant immunization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Infants born to HBsAg-positive mothers and infants born to women whose HBsAg status remains unknown indefinitely should have postvaccination serology (both HBsAg and antibody to HBsAg) after receiving ≥3 doses of HepB vaccine, usually at 9 to 12 months of age  (
         <a class="graphic graphic_algorithm graphicRef116953" href="/z/d/graphic/116953.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef101871" href="/z/d/graphic/101871.html" rel="external">
          table 7
         </a>
         ). (See
         <a class="local">
          'HBsAg-positive mother or mother with other evidence of HBV infection'
         </a>
         above and
         <a class="local">
          'Postvaccination serology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Catch-up immunization
         </strong>
         – In the United States, catch-up HepB immunization is indicated for all children and adolescents &lt;19 years of age  (
         <a class="graphic graphic_table graphicRef116656" href="/z/d/graphic/116656.html" rel="external">
          table 4
         </a>
         ) (see
         <a class="local">
          'Catch-up immunization'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Who are unvaccinated or incompletely vaccinated against hepatitis B virus
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Whose HepB immunization status is unknown or uncertain
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Who received doses of HepB vaccine that were administered inappropriately
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaccine administration
         </strong>
         – The dose of HepB vaccine varies with the recipient's age and whether the recipient is receiving hemodialysis or is immune compromised  (
         <a class="graphic graphic_table graphicRef60075" href="/z/d/graphic/60075.html" rel="external">
          table 1
         </a>
         ). HepB vaccine is administered intramuscularly, usually in the anterolateral thigh for children &lt;3 years and the deltoid for children ≥3 years  (
         <a class="graphic graphic_table graphicRef60863" href="/z/d/graphic/60863.html" rel="external">
          table 3
         </a>
         ). Different limbs should be used if HepB vaccine and HBIG are administered at the same time (ie, same day, same clinic visit). The injections may be administered in any order. (See
         <a class="local">
          'Vaccine administration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications and precautions
         </strong>
         – Contraindications to HepB vaccine include hypersensitivity to yeast or to any vaccine component  (
         <a class="graphic graphic_table graphicRef101869" href="/z/d/graphic/101869.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="local">
          'Contraindications and precautions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse reactions
         </strong>
         – HepB vaccines are safe; the most frequently reported side effects are pain at the injection site and low-grade fever. (See
         <a class="local">
          'Adverse reactions'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018; 67:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith EA, Jacques-Carroll L, Walker TY, et al. The national Perinatal Hepatitis B Prevention Program, 1994-2008. Pediatrics 2012; 129:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margolis HS, Coleman PJ, Brown RE, et al. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995; 274:1201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977; 105:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2:1129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis and the "healthy" HBsAg carrier state. Hepatology 1987; 7:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMahon BJ, Alberts SR, Wainwright RB, et al. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990; 150:1051.
          </a>
         </li>
         <li class="breakAll">
          Engerix-B. US Food &amp; Drug Administration (FDA) approved product information. Revised November 2013. Available at: www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm093833.htm (Accessed on May 29, 2015).
         </li>
         <li class="breakAll">
          Recombivax HB. US Food &amp; Drug Administration (FDA) approved product information. Revised May 2014. Available at: www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm093833.htm (Accessed on May 29, 2015).
         </li>
         <li class="breakAll">
          Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined. US Food &amp; Drug Administration (FDA) approved product information. Revised November 2013. Available at: www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm093833.htm (Accessed on May 29, 2015).
         </li>
         <li class="breakAll">
          Twinrix. US Food &amp; Drug Administration (FDA) approved product information. Revised November 2013. Available at: www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm093833.htm (Accessed on May 29, 2015).
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Hepatitis B. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.381.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seto D, West DJ, Gilliam RR, et al. Antibody responses of healthy neonates of two mixed regimens of hepatitis B vaccine. Pediatr Infect Dis J 1999; 18:840.
          </a>
         </li>
         <li class="breakAll">
          Vaxelis (Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, Haemophilus b conjugate [meningococcal protein conjugate] and hepatitis B [recombinant] vaccine. United States Prescribing Information. Revised December, 2018. US Food &amp; Drug Administration. Available online: https://www.fda.gov/BiologicsBloodVaccines/ucm629107.htm (Accessed on December 28, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliver SE, Moore KL. Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants. MMWR Morb Mortal Wkly Rep 2020; 69:136.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Current vaccine shortages and delays. Available at: www.cdc.gov/VACCINes/vac-gen/shortages/default.htm (Accessed on January 08, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langley JM, Halperin SA, Rubin E, et al. Safety and immunogenicity of 2 mixed primary infant immunization schedules of pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae Type B vaccines at 2, 4, and 6 months of age: a randomized controlled trial. Pediatr Infect Dis J 2012; 31:189.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Pertussis. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S (Eds). Public Health Foundation, Washington, DC 2015. Available at: www.cdc.gov/vaccines/pubs/pinkbook/index.html (Accessed on June 02, 2015).
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Hepatitis B. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S (Eds). Public Health Foundation, Washington, DC 2015. Available at: www.cdc.gov/vaccines/pubs/pinkbook/index.html#toc (Accessed on May 20, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Implementation of newborn hepatitis B vaccination--worldwide, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hepatitis B vaccines: WHO position paper – July 2017. Wkly Epidemiol Rec 2017; 92:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wodi AP, Murthy N, McNally V, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           COMMITTEE ON INFECTIOUS DISEASES, COMMITTEE ON FETUS AND NEWBORN. Elimination of Perinatal Hepatitis B: Providing the First Vaccine Dose Within 24 Hours of Birth. Pediatrics 2017; 140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975; 292:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson NP, Jamieson DJ, Murphy TV. Prevention of Perinatal Hepatitis B Virus Transmission. J Pediatric Infect Dis Soc 2014; 3 Suppl 1:S7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee C, Gong Y, Brok J, et al. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2006; :CD004790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schillie S, Walker T, Veselsky S, et al. Outcomes of infants born to women infected with hepatitis B. Pediatrics 2015; 135:e1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Postvaccination serologic testing results for infants aged ≤24 months exposed to hepatitis B virus at birth: United States, 2008-2011. MMWR Morb Mortal Wkly Rep 2012; 61:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan CX, Chan SM, Lee LY, et al. Serologic Responses After Hepatitis B Vaccination in Preterm Infants Born to Hepatitis B Surface Antigen-Positive Mothers: Singapore Experience. Pediatr Infect Dis J 2017; 36:e208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pichichero ME, Blatter MM, Reisinger KS, et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J 2002; 21:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Losonsky GA, Wasserman SS, Stephens I, et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics 1999; 103:E14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belloni C, Chirico G, Pistorio A, et al. Immunogenicity of hepatitis B vaccine in term and preterm infants. Acta Paediatr 1998; 87:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadler SC, de Monzon MA, Lugo DR, Perez M. Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. Vaccine 1989; 7:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halsey NA, Moulton LH, O'Donovan JC, et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics 1999; 103:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989; 160:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schönberger K, Riedel C, Rückinger S, et al. Determinants of Long-term protection after hepatitis B vaccination in infancy: a meta-analysis. Pediatr Infect Dis J 2013; 32:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marion SA, Tomm Pastore M, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol 1994; 140:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yusuf HR, Daniels D, Smith P, et al. Association between administration of hepatitis B vaccine at birth and completion of the hepatitis B and 4:3:1:3 vaccine series. JAMA 2000; 284:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauderdale DS, Oram RJ, Goldstein KP, Daum RS. Hepatitis B vaccination among children in inner-city public housing, 1991-1997. JAMA 1999; 282:1725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luman ET, Fiore AE, Strine TW, Barker LE. Impact of thimerosal-related changes in hepatitis B vaccine birth-dose recommendations on childhood vaccination coverage. JAMA 2004; 291:2351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chawareewong S, Jirapongsa A, Lokaphadhana K. Immune response to hepatitis B vaccine in premature neonates. Southeast Asian J Trop Med Public Health 1991; 22:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau YL, Tam AY, Ng KW, et al. Response of preterm infants to hepatitis B vaccine. J Pediatr 1992; 121:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linder N, Vishne TH, Levin E, et al. Hepatitis B vaccination: long-term follow-up of the immune response of preterm infants and comparison of two vaccination protocols. Infection 2002; 30:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel DM, Butler J, Feldman S, et al. Immunogenicity of hepatitis B vaccine in healthy very low birth weight infants. J Pediatr 1997; 131:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blondheim O, Bader D, Abend M, et al. Immunogenicity of hepatitis B vaccine in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998; 79:F206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang FY, Lee PI, Lee CY, et al. Hepatitis B vaccination in preterm infants. Arch Dis Child Fetal Neonatal Ed 1997; 77:F135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SC, Chung EK, Hodinka RL, et al. Immunogenicity of hepatitis B vaccine in preterm infants. Pediatrics 1997; 99:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qu C, Chen T, Fan C, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med 2014; 11:e1001774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiang CJ, Yang YW, You SL, et al. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013; 310:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruce MG, Bruden D, Hurlburt D, et al. Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. J Infect Dis 2016; 214:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009; 200:1390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang KC, Chang MH, Chen HL, et al. Universal Infant Hepatitis B Virus (HBV) Vaccination for 35 Years: Moving Toward the Eradication of HBV. J Infect Dis 2022; 225:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Middleman AB, Baker CJ, Kozinetz CA, et al. Duration of protection after infant hepatitis B vaccination series. Pediatrics 2014; 133:e1500.
          </a>
         </li>
         <li class="breakAll">
          Immunization Action Coalition. Ask the Experts: Diseases &amp; Vaccines. Hepatitis B. http://www.immunize.org/askexperts/experts_hepb.asp#recommendations (Accessed on July 07, 2016).
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. General best practice guidelines for immunization. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html (Accessed on May 16, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaw FE Jr, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989; 7:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook IF, Murtagh J. Comparative immunogenicity of hepatitis B vaccine administered into the ventrogluteal area and anterolateral thigh in infants. J Paediatr Child Health 2002; 38:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Redfield RR, Innis BL, Scott RM, et al. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA 1985; 254:3203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman PJ, Shaw FE Jr, Serovich J, et al. Intradermal hepatitis B vaccination in a large hospital employee population. Vaccine 1991; 9:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gasparini R, Tregnaghi M, Keshavan P, et al. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration. Pediatr Infect Dis J 2016; 35:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023. MMWR Recomm Rep 2023; 72:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kloster B, Kramer R, Eastlund T, et al. Hepatitis B surface antigenemia in blood donors following vaccination. Transfusion 1995; 35:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lunn ER, Hoggarth BJ, Cook WJ. Prolonged hepatitis B surface antigenemia after vaccination. Pediatrics 2000; 105:E81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azhar Z, Purcell R, Buttery J, Doherty R. Hepatitis B Testing: Old Tricks for Newborn Players. Pediatr Infect Dis J 2020; 39:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Notice to readers: Alternate two-dose hepatitis B vaccination schedule for adolescents aged 11 to 15 years. MMWR Morb Mortal Wkly Rep 2000; 49:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal safety. Am J Perinatol 1991; 8:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis E, Shinefield HR, Woodruff BA, et al. Safety of neonatal hepatitis B vaccine administration. Pediatr Infect Dis J 2001; 20:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Euler GL, Copeland JR, Rangel MC, Williams WW. Antibody response to postexposure prophylaxis in infants born to hepatitis B surface antigen-positive women. Pediatr Infect Dis J 2003; 22:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ko SC, Schillie SF, Walker T, et al. Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women. Vaccine 2014; 32:2127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lolekha S, Warachit B, Hirunyachote A, et al. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 2002; 20:3739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assateerawatt A, Tanphaichitr VS, Suvatte V, Yodthong S. Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates, school children and healthy adults. Asian Pac J Allergy Immunol 1993; 11:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan KL, Goh KT, Oon CJ, Chan SH. Immunogenicity of recombinant yeast-derived hepatitis B vaccine in nonresponders to perinatal immunization. JAMA 1994; 271:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 1988; 109:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hovi L, Valle M, Siimes MA, et al. Impaired response to hepatitis B vaccine in children receiving anticancer chemotherapy. Pediatr Infect Dis J 1995; 14:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson CM, Ellenberg JH, Sawyer MK, et al. Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. Reaching for Excellence in Adolescent Care and Health. J Adolesc Health 2001; 29:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polychronopoulou-Androulakaki S, Panagiotou JP, Kostaridou S, et al. Immune response of immunocompromised children with malignancies to a recombinant hepatitis B vaccine. Pediatr Hematol Oncol 1996; 13:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuin G, Principi N, Tornaghi R, et al. Impaired response to hepatitis B vaccine in HIV infected children. Vaccine 1992; 10:857.
          </a>
         </li>
         <li class="breakAll">
          Smitherman L, Favier N, Aljaberi S, et al. Waning hepatitis B immunity status in a significant proportion of immunocompromised pediatric rheumatology and gastroenterology patients. Abstract and platform presentation, Pediatric Academic Societies Meeting, San Francisco, CA, May 2017. https://www.pas-meeting.org/ (Accessed on May 16, 2017).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 101483 Version 55.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29939980" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22451702" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The national Perinatal Hepatitis B Prevention Program, 1994-2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7563509" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/835566" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The e antigen and vertical transmission of hepatitis B surface antigen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6118576" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3301618" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Chronic type B hepatitis and the "healthy" HBsAg carrier state.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2158773" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2158773" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2158773" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2158773" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2158773" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2158773" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10493355" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Antibody responses of healthy neonates of two mixed regimens of hepatitis B vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10493355" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Antibody responses of healthy neonates of two mixed regimens of hepatitis B vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32027629" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32027629" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22173143" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Safety and immunogenicity of 2 mixed primary infant immunization schedules of pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae Type B vaccines at 2, 4, and 6 months of age: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22173143" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Safety and immunogenicity of 2 mixed primary infant immunization schedules of pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae Type B vaccines at 2, 4, and 6 months of age: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22173143" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Safety and immunogenicity of 2 mixed primary infant immunization schedules of pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae Type B vaccines at 2, 4, and 6 months of age: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19023261" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Implementation of newborn hepatitis B vaccination--worldwide, 2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28685564" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Hepatitis B vaccines: WHO position paper–July 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36757872" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28847980" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Elimination of Perinatal Hepatitis B: Providing the First Vaccine Dose Within 24 Hours of Birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1113797" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Vertical transmission of hepatitis B antigen in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25232477" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Prevention of Perinatal Hepatitis B Virus Transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16625613" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25896839" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Outcomes of infants born to women infected with hepatitis B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23013723" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Postvaccination serologic testing results for infants aged≤24 months exposed to hepatitis B virus at birth: United States, 2008-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28198787" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Serologic Responses After Hepatitis B Vaccination in Preterm Infants Born to Hepatitis B Surface Antigen-Positive Mothers: Singapore Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12352809" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9925860" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9560044" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Immunogenicity of hepatitis B vaccine in term and preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2526419" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10353936" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Hepatitis B vaccine administered to children and adolescents at yearly intervals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2530289" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Vaccination against hepatitis B: comparison of three different vaccination schedules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23249904" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Determinants of Long-term protection after hepatitis B vaccination in infancy: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7942775" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Long-term follow-up of hepatitis B vaccine in infants of carrier mothers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10944643" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Association between administration of hepatitis B vaccine at birth and completion of the hepatitis B and 4:3:1:3 vaccine series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10568644" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Hepatitis B vaccination among children in inner-city public housing, 1991-1997.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15150207" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Impact of thimerosal-related changes in hepatitis B vaccine birth-dose recommendations on childhood vaccination coverage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1835140" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Immune response to hepatitis B vaccine in premature neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1447667" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Response of preterm infants to hepatitis B vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12120937" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Hepatitis B vaccination: long-term follow-up of the immune response of preterm infants and comparison of two vaccination protocols.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9386675" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Immunogenicity of hepatitis B vaccine in healthy very low birth weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10194993" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Immunogenicity of hepatitis B vaccine in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9377137" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Hepatitis B vaccination in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9093293" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Immunogenicity of hepatitis B vaccine in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25549238" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24002285" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Thirty-year outcomes of the national hepatitis B immunization program in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26802139" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19785526" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34363469" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Universal Infant Hepatitis B Virus (HBV) Vaccination for 35 Years: Moving Toward the Eradication of HBV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24843060" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Duration of protection after infant hepatitis B vaccination series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24843060" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Duration of protection after infant hepatitis B vaccination series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24843060" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Duration of protection after infant hepatitis B vaccination series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2530717" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12174003" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Comparative immunogenicity of hepatitis B vaccine administered into the ventrogluteal area and anterolateral thigh in infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2933535" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1836918" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Intradermal hepatitis B vaccination in a large hospital employee population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26398743" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36893044" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7770897" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Hepatitis B surface antigenemia in blood donors following vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10835094" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Prolonged hepatitis B surface antigenemia after vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32091500" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Hepatitis B Testing: Old Tricks for Newborn Players.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Notice to readers: Alternate two-dose hepatitis B vaccination schedule for adolescents aged 11 to 15 years
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1827584" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Hepatitis B vaccine in pregnancy: maternal and fetal safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11734710" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Safety of neonatal hepatitis B vaccine administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14523172" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Risk of anaphylaxis after vaccination of children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12586975" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Antibody response to postexposure prophylaxis in infants born to hepatitis B surface antigen-positive women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24560676" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12399203" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8216564" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates, school children and healthy adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8114241" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Immunogenicity of recombinant yeast-derived hepatitis B vaccine in nonresponders to perinatal immunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29405329" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2968064" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8584357" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Impaired response to hepatitis B vaccine in children receiving anticancer chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11530313" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. Reaching for Excellence in Adolescent Care and Health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10897814" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Immune response of immunocompromised children with malignancies to a recombinant hepatitis B vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1455911" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Impaired response to hepatitis B vaccine in HIV infected children.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
